---
schema_version: "secwatch.filing_event.v1"
accession: "0001520138-22-000548"
form_type: "8-K"
ticker: "BIVI"
cik: "0001580149"
company_name: "BIOVIE INC."
filed_at: "2022-12-06T23:59:59+00:00"
generated_at: "2026-06-21T08:53:01.043567+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioVie announces positive Phase 2 results for NE3107 in Parkinson's and Alzheimer's; epigenetic age reduced 3.3 years

## Summary
- PD trial: NE3107+levodopa improved UPDRS Part 3 by 3+ points vs levodopa alone; under-70 patients saw 6-point superiority.
- AD trial: 2.1-point improvement on ADAS-Cog12 (p=0.0173) in MCI/mild AD patients; CSF p-tau reduced by 1.66 pg/mL.
- 18 of 22 AD patients showed improvement on functional MRI; no drug-related adverse events reported.
- DNA methylation analysis: Horvath SkinBlood clock reduced by 3.3 years (p=0.0021) after 3 months; 19 of 22 patients showed reduction.
- Full Parkinson's data to be presented at AD/PD 2023 conference in March-April 2023.

## SEC filing metadata
- accession: 0001520138-22-000548
- form_type: 8-K
- ticker: BIVI
- cik: 0001580149
- company_name: BIOVIE INC.
- filed_at: 2022-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580149/000152013822000548/0001520138-22-000548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580149/000152013822000548/bivi-20221205_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001520138-22-000548
- JSON: https://secwatch.observer/filing/0001520138-22-000548.json
- Plain text: https://secwatch.observer/filing/0001520138-22-000548.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.